PharmaTimesOriginal article
Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
Phase 2positivenipocalimabPositive
AI Analysis
Summary
Johnson & Johnson reported Phase 2 data for nipocalimab demonstrating reduced SLE disease activity with sustained responses through week 52, presented as late-breaking results at EULAR.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Nipocalimab reduced SLE disease activity with sustained responses through week 52
Importance:6/10
Sentiment:
0.75
Phase 2 dataSLEEULARlate-breaking results
Related Companies
Read the original article
Published by PharmaTimes on June 4, 2026 10:10 AM